**4. Conclusion**

Antiplatelet therapy with ASA is the cornerstone of treatment in coronary artery disease pa‐ tients especiallity after CABG surgery. The question of ASA resistence can be defined clini‐ cally as an ischaemic even while on ASA treatment daily. Laboratory assays of ASA response are surrogate measures as platelet aggregation inhibitor in *vitro* does not coinci‐ dentally translate into prevention of thrombosis in *vivo*, however the tests are not compari‐ bale among themself. Clinical studies are needed to discover the optimal dosing and the clinical significance of laboratory aspirin resistance for sufficiency of graft function.
